PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 22, 2026Sensors & DiagnosticsOpen Access

Translational opportunities in aptamer and nanobody lateral flow assays within the WHO REASSURED framework

View Full Paper
Ask AI
Bookmark
Share

Authors

EME. MonkEMErin M. McConnellDMDavid McMullin

Discussion

Loading...

Member takes

Overview

Translational progress shows regulatory constraints on aptamer and nanobody assays, indicating the need for updated guidelines.

Key Points

  • The study aims to explore the translational opportunities for aptamer and nanobody lateral flow assays within regulatory frameworks.
  • Discussed the analytical performance of aptamer and nanobody assays compared to traditional antibody assays.
  • Analyzed the impact of existing regulatory frameworks on the approval process for these assays.
  • Aptamer and nanobody lateral flow assays exhibit performance comparable to antibodies.
  • Current regulations remain heavily biased towards antibodies, hindering new assay adoption.

Cite This Study

Monk et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff362d674f7c03778c0c0https://doi.org/10.1039/d6sd00028b
View Full Paper
Ask AI
Bookmark
Share